Value Based Healthcare – A Reality

This exhibition brings a unique visitor experience towards Roche commitment to personalized healthcare and its impact on the people’s lives, shifting from a one-size-fits-all approach to the best care for each person.

Date & Time
agenda-icon Friday, November, 26, 2021
agenda-icon 00 : 00
agenda-icon Friday, December, 10, 2021
agenda-icon 00 : 00

This year, Roche celebrates lifeBecause life is about celebration – whether creating new memories that resonate for years or pausing to reflect on the small precious moments of our past. As an official participant in the Swiss Pavilion, Roche will be launching “Expo What if LifeTalk”, an exclusive forum as part of Roche’s 125-year anniversary programme aimed at exploring and shaping the future of healthcare through collaboration and dialogue that fits innovative ideas around value based healthcare, digital innovation and value of diagnostics in the Middle East region and beyond.



Roche is the world’s largest biotech company, with truly differentiated medicines in oncology, immunology, infectious diseases, ophthalmology and diseases of the central nervous system. Roche is also the world leader in in vitro diagnostics and tissue-based cancer diagnostics, and a frontrunner in diabetes management. In recent years, Roche has invested in genomic profiling and real-world data partnerships and has become an industry-leading partner for medical insights.

The company’s research institutes, the Basel Institute for Immunology and Roche Institute of Molecular Biology, have also been the centre of many significant breakthroughs in scientific research, with three Nobel prizes to their credit. These major contributions to people’s health are currently reflected in the 32 Roche medicines that are listed on the World Health Organization (WHO) Model List of Essential Medicines. In 2020 alone, 28.9 million patients were treated with Roche medicines and 23.4 billion tests were conducted with Roche Diagnostics. Roche expenditure on research and development came to more than 13 billion Swiss francs. For more information, visit